Partner: Guerbet SA
Eric Lancelot got his doctorate in pharmacy in Paris in 1990. In 1996, he obtained a PhD in pharmacology in the field of cerebral ischemia. Then, he performed post-doctoral studies at the Massachusetts General Hospital, Boston, USA, on the neurodegenerative mechanisms of Huntington’s and Parkinson’s diseases.
Since 1998, Eric Lancelot has been working in Guerbet, a French pharmaceutical company involved in the research, development, marketing and sales of contrast media and medical devices for diagnostic and interventional radiology. He spent twelve years in the Research Division as Manager of the Biological Research Department. With a team of 20 collaborators, he investigated the pharmacokinetic, pharmacodynamic and toxicological properties of contrast agents for X-Rays, MRI and PET. He was also involved in molecular imaging in the fields of cardiovascular, tumoral, inflammatory and neurodegenerative diseases.
In 2010, Eric Lancelot became the Head of Regulatory and Medical Affairs – Europe for Guerbet. He is the functional manager of the Regulatory and Medical Affairs Managers in the eleven European subsidiaries of the Group. He coordinates their activities (clinical studies, pharmacovigilance, quality assurance, medical information, regulatory affairs), support to the design of Guerbet-sponsored and investigator-initiated clinical studies. He provide scientific support to the marketing and sales teams in the subsidiaries, and his expert contribution to working groups about clinical, pathophysiological, pharmaco-toxicological and radiological matters related to the use of contrast media.
Eric Lancelot is a member of the French Society of Radiology (SFR) and of the Contrast Media Safety Committee of the European Society of Urologic Radiology (ESUR).
Eric Lancelot’s publications :
- 20 articles about molecular or cellular imaging in pathological models.
- 10 articles about the safety and pharmacokinetic profiles of contrast agents for X-Rays or MRI.
- 9 articles about cerebral ischemia and chronic neurodegenerative diseases.
- Patent n°IB2004002193 approved by the European Patent Office.
Professional address: GUERBET BP 57400, 95943 Roissy CdG Cedex